Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients who had melanoma – a dangerous type of skin cancer.
Blog
Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients who had melanoma – a dangerous type of skin cancer.
